InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...
City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national nonprofit ...
Jersey City-based Character Biosciences has announced a collaboration with Bausch + Lomb to develop innovative treatments for ...
The stock of eyecare company Bausch + Lomb Corp. was up 14%on Monday ... issues given its Restasis has a 45% share of the prescription dry-eye market. “Given these points, a sale to a strategic ...
Hosted on MSN1mon
Eye health company Bausch + Lomb’s affiliate acquires Elios VisionElios Vision former chairman and CEO Elliot Friedman said: “Bausch + Lomb’s extensive reach in cataract surgery will introduce ELIOS to a broader range of eye care professionals and help ...
Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback